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combination of surgery, chemotherapy and radiation therapy. 
The side effects still are the main limitation of brain tumors’ 
treatment by radiotherapy and do not allow the dose 
escalation needed to treat these highly radio-resistant 
tumors. In this research program, we propose a new FLASH 
radiotherapy modality based on the dose delivery at ultrahigh 
dose-rate (above 50Gy/s), which has shown an important 
differential effect with the protection of normal tissues and 
stem cells and an efficient antitumor effect (Favaudon et al. 
2014).  
Materials and Methods: Two LINACs prototypes are used: a 
4.5 MeV (Institut Curie) and a 6 MeV (CHUV) to investigate 
the normal brain response and the antitumor effect of FLASH 
irradiation on GBM models in a preclinical study with an 
ultimate aim to apply this treatment to GBM bearing 
patients. For the studies on normal brain, C57Bl6/J mice 
were irradiated at the whole brain level at single doses 
ranging from 10 to 80 Gy FLASH (>50Gy/s), at 10 Gy CONV 
(0.04Gy/s) and sham irradiated (6 mice in each group). Two 
months post-irradiation, cognitive tests were performed on 
mice to evaluate the mid-term memory with a novel object 
recognition test (Acharya et al. 2009) and brains were 
sampled. Two hours before the sampling, mice were injected 
with BrdU, brains were collected and immunohistochemistry 
and NSCs quantification were performed on brain sections. To 
evaluate the FLASH antitumor effect, human GBM were 
engrafted to nude mice. The tumors were locally irradiated 
at 10 Gy CONV, from 10 to 30 Gy FLASH and sham irradiated. 
Tumor growth delay was measured.  
Results: Our preliminary results show that 50Gy FLASH 
irradiation on the whole brain does not induce any 
macroscopic toxicity nor mice’s health alteration whereas a 
pan-encephalic irradiation of 10Gy CONV is the maximum 
tolerated dose for long term follow-up. The cognitive tests’ 
results show a drop in cognitive skills after 10Gy CONV 
irradiation whereas mid-term visual memorization is not 
significantly affected at 50Gy FLASH. In correlation, two 
months after irradiation, the quantification of NSCs shows 
their preservation in the SGZ at doses up to 20Gy FLASH 
whereas 10Gy CONV eradicates all the hippocampal NSCs at 
the same timepoint. Astrocytic toxicity has also been 
investigated and shows that 10Gy CONV irradiation induces a 
high level of gliosis and astrocytes’ remodeling whereas few 
gliosis and astrocytes’ modifications are observed after 50Gy 
FLASH. At the tumor level and at similar doses, the FLASH 
and CONV irradiations induce a similar growth retardation. 
Nevertheless, the FLASH irradiation’s innocuousness on 
normal tissue does allow a dose escalation and thus an 
enhancement of the tumor growth delay. We are currently 
escalading the dose to achieve the tumor control. 
Conclusions: Altogether these results suggest that the FLASH 
radiotherapy allows the delivery of very high doses to the 
whole brain, sparing normal tissues and NSCs and eradicating 
tumor cells. In the follow up of these preliminary 
experiments we are developing orthotopic and spontaneous 
GBM models in mice (in collaboration with K. Shchors and D. 
Hanahan, EPFL) to define the molecular basis of the FLASH 
differential effect. 
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Purpose/Objective: To evaluate clinical-radiological 
response and outcome in soft tissue sarcomas of extremities, 
in patients treated with neoadjuvant radiochemotherapy. 
Materials and Methods: 74 patients (25 females, 49 males; 
median age 53.7 years, range: 27-87), were treated with 
neoadjuvant chemotherapy (CT) and radiotherapy (RT). 
Selection criteria were diseases of large dimension or in close 
proximity of critical structures such as nerves or vessels. 
Based on RMN images, the Gross Tumor Volume (GTV), 
defined as the macroscopic volume of disease visible in the 
T1-weighted sequences, was included. MRI images were 
merged with those of TC-simulation. For CTV definition, an 
expansion of 4 cm in cranio-caudal (except where anatomical 
barriers were present) and 1 cm in anterior-posterior and 
lateral-side was given to the GTV. PTV was defined as CTV + 
1 cm isotropically. All patients underwent CT, MRI +/- PET 
before RT, at the end of RT (before surgery) and during 
follow-up (FU). 
Results: At preoperative MRI revaluation the volumetric size 
of the tumor showed an average reduction of 34% (range 
+83.0% to -88.8%). Only 24 patients (32.4%) needed an 
adjuvant RT-boost for marginal or intralesional margins. Only 
three patients had local relapse at 3-13-31 months after 
surgery and were treated with surgical resection or 
brachytherapy, with local control of the disease in the 
following radiological-clinical controls. Patients with smaller 
tumors (< median) and better clinical response (> median) 
showed a trend for improved disease free survival at 5 years 
(92.9% vs 61.8%; p=0.058). Twenty patients developed 
metastases during the FU (90% lung metastases). Two out of 
74 patients died. With a median FU of 46.4 months (range 6-
113 months) 12.8% of patients showed lymphedema, 10.8% 
had mild functional impairment and 5.4% reported reduced 
sensibility in the treated site.  
Conclusions: The preoperative approach allowed to irradiate 
smaller volumes compared to adjuvant RT and to deliver 
lower doses (50 Gy/25 fractions + 20 Gy boost only in case of 
positive margins, versus 60-66 Gy/30 fractions). Neoadjuvant 
RT produced a significant reduction of the tumor volume, 
allowing a less invasive and more conservative surgical 
approach, and high long-term local control rates. 
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Purpose/Objective: Hippocampal-avoiding whole brain 
radiotherapy (HA-WBRT) for multiple brain metastases may 
prevent treatment-related cognitive decline, compared to 
standard WBRT. Reduction in hippocampal volume over time 
has been shown to be significantly related to decline in 
memory and learning. This study aims at exploring brain 
volume changes after whole brain radiotherapy with 
hippocampal avoidance (HA-WBRT). 
Materials and Methods: 22 patients who had been assigned 
to HA-WBRT following clinical indication received MRI before 
and up to 19 months after treatment (Mean = 5 months). 
Observer-independent, automated volumetry of the 
hippocampi, the lateral ventricles, and the whole brain was 
performed on 77 MRI data sets using Matlab and statistical 
parametric mapping (SPM8). Longitudinal volumes have been 
tested for significant brain changes after HA-WBRT. Linear 
mixed models were computed with regional volumes as 
dependent variables and predictor variable time with random 
intercepts and slopes for time across subjects and variance 
components as covariance structure (controlling for age). 
Volume change rates after RT have been calculated for each 
region. 
Results: At the group level, hippocampal [-0.02 ml (-0.19%) 
per month] and whole brain volumes [-2.03 ml (-0.19%) per 
month] showed decreases which did not reach significance. 
By contrast, the lateral ventricles significantly expanded [p < 
0.0001; +1.2 ml (3.6%) per month (43% per year)]. 
Conclusions: In this pilot study we observed no significant 
hippocampal atrophy after HA-WBRT. The lateral ventricles, 
however, expanded after treatment, indicating cerebral 
atrophy at a higher rate than reported in the literature on 
healthy subjects. While brain tissue degeneration seems to 
occur in this group of patients, hippocampal tissue is spared 
from this process. 
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Purpose/Objective: Local control (LC) rate is inversely 
related to the volume and size of the brain metastases 
treated with SRS. We aimed to demonstrate the potential 
role of fSRT with increasing volumes in order to improve LC. 
Materials and Methods: Between 2001-2004, 180 patients 
with brain metastases were treated with stereotactic 
radiosurgery (SRS) or fractionated stereotactic radiotherapy 
(fSRT). Sixty-five percent were treated for newly diagnosed, 
whereas 35% for progressive brain metastases after previous 
whole brain radiotherapy. Median number of metastases was 
2 and distributed as single 43%, 2-3 mets 33%, 4-10 mets 16% 
and >10 mets 8%. Median age was 59 years (29-87 years); 38% 
was female, 62% male. Primary tumor site was lung in 65%, 
breast in 16%, gastrointestinal 7%, kidney 5%, melanoma 2% 
and others 5%. Patients were grouped according to the 
diameter of the largest metastasis as ≤10mm in 15%, 11-
20mm in 36%, 21-30 mm in 31% and >30 mm in 18%. Patient 
fixation was made with thermoplastic masks. CT and MR 
simulation with contrast was made on-site at the same day. 
GTV was equal to PTV. All treatments were performed on 
TrueBeam STx with Novalis (Varian, Palo Alto, USA and 
BrainLAB AG, Feldkirchen, Germany) using flattening filter 
free beams and non-coplanar multiple partial arcs. Decision 
for fractionation was made according to the size of the 
largest metastasis, cumulative volume and location of the 
metastases. Percentage of fSRT in diameters of ≤10mm, 11-
20mm, 21-30 mm and >30 mm were 15%, 57%, 91% and 100%. 
Median peripheral doses were 18 Gy for single fraction (14-20 
Gy), 24 Gy for 3 fractions (18-27 Gy) and 30 Gy for 5 fractions 
(22.5-40 Gy) treatments. 
Results: At a median follow-up of 6 months (1-38 months) 
median overall survival (OS) was 12 months for the whole 
group (newly diagnosed group 13 months, progressive group 8 
months, p=0.004). OS curves separated significantly in 
patients with ≤20mm, 21-30 mm and >30mm diameters with 
median OS as 17, 12 and 7 months, respectively (p<0.01). LC 
at 1 year for the newly diagnosed patients was 79%, and for 
the progressive patients 69% (p<0.01). One-year LC rate for 
≤10mm, 11-20mm, 21-30 mm and >30 mm diameter was 
100%, 74%, 70% and 69%, respectively (p=0.02, for ≤10mm vs 
others). Specifically in the group with large metastases (>30 
mm, n=33) all of whom were treated with fSRT, one-year LC 
rate was 100% for the newly diagnosed patients, and 47% for 
progressive patients. Salvage treatment was performed as 
SRS in 25 patients (14%), WBRT in 7 patients (4%) and surgery 
in 2 patients. Repeat SRS to the same target was done in one 
patient. Radionecrosis was observed in 10 patients (5.6%), 
and all were treated with steroids or bevacizumab without 
surgery. 
Conclusions: Single fraction SRS can achieve high local 
control for small brain metastases. For larger metastases 
fSRT can successfully replace SRS with improved LC and lower 
toxicity. 
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